To see the other types of publications on this topic, follow the link: Systemic diseases and oral ulcers.
Journal articles on the topic 'Systemic diseases and oral ulcers'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Systemic diseases and oral ulcers.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Minhas, Sadia, Aniqa Sajjad, Muhammad Kashif, Farooq Taj, Hamed Alwadaani, and Zohaib Khurshid. "Oral Ulcers Presentation in Systemic Diseases: An Update." Open Access Macedonian Journal of Medical Sciences 7, no. 19 (October 10, 2019): 3341–47. http://dx.doi.org/10.3889/oamjms.2019.689.
Full textAbstract:
BACKGROUND: Diagnosis of oral ulceration is always challenging and has been the source of difficulty because of the remarkable overlap in their clinical presentations.
AIM: The objective of this review article is to provide updated knowledge and systemic approach regarding oral ulcers diagnosis depending upon clinical picture while excluding the other causative causes.
METHODS: For this, specialised databases and search engines involving Science Direct, Medline Plus, Scopus, PubMed and authentic textbooks were used to search topics related to the keywords such as oral ulcer, oral infections, vesiculobullous lesion, traumatic ulcer, systematic disease and stomatitis. Associated articles published from 1995 to 2019 in both dental and medical journals including the case reports, case series, original articles and reviews were considered.
RESULTS: The compilation of the significant data reveals that ulcers can be classified according to (i) duration of onset, (ii) number of ulcers and (iii) etiological factors. Causation of oral ulcers varies from slight trauma to underlying systemic diseases and malignancies.
CONCLUSION: Oral manifestations must be acknowledged for precise diagnosis and appropriate treatment.
2
Samad, Tabassum, Jamal Uddin Ahmed, Muhammad Abdur Rahim, AKM Musa, Khwaja Nazim Uddin, AKM Shaheen Ahmed, and Hasna Fahmima Haque. "Behcets Disease Presenting as Fever of Unknown Origin : A Case Report." BIRDEM Medical Journal 3, no. 1 (November 24, 2013): 50–53. http://dx.doi.org/10.3329/birdem.v3i1.17128.
Full textAbstract:
Behcets disease (BD) is an inflammatory disease characterized by recurrent oral aphthous ulcers and numerous systemic manifestations. The underlying cause of Behcets disease is unknown. As with other autoimmune diseases, the disorder may represent aberrant immune activity triggered by exposure to an antigen, perhaps infectious, in patient with a genetic predisposition to develop the disease. Here we are reporting a case of Behcets disease in a 50 year old gentleman who presented with fever, recurrent oral ulcers and genital ulcer. Diagnostic workup excluded other possible diseases. Pathergy test was positive. Prednisolone was started along with other supportive therapy and patient subsequently improved. Birdem Med J 2013; 3(1): 50-53 DOI: http://dx.doi.org/10.3329/birdem.v3i1.17128
3
Singh, Himanshu, Vedant Patel, Rahul A. Razdan, Resham Maheshwari, Sourabh Sharma, and Divya Jain. "Knowledge of Systemic Diseases Presenting the Oral Signs and Symptoms: A Short Review." Dental Journal of Advance Studies 07, no. 02 (August 2019): 056–60. http://dx.doi.org/10.1055/s-0039-1698361.
Full textAbstract:
AbstractThe accurate examination of oral cavity may acknowledge findings that demonstrate the presence of underlying systemic, which helps in earlier diagnosis as well as treatment. The oral tissues are accountable to damage as a disease consequence that primarily affects other body systems. Various systemic diseases show oral manifestation. Some of these oral conditions include oral ulcers, caries, dry mouth, gingival bleeding, and gingival hypertrophy. This review article is prepared to make general physicians as well as dentist aware about systemic disorders or conditions that show dental or oral manifestation.
4
Aralova, Masha V., and Aleksandr A. Glukhov. "Clinical case of the treatment of venous leg ulcers in a patient with Sjogren disease." Vestnik of Experimental and Clinical Surgery 10, no. 4 (December 31, 2017): 315–19. http://dx.doi.org/10.18499/2070-478x-2017-10-4-315-319.
Full textAbstract:
Relevance. Trophic ulcers on the background of systemic diseases are characterized by long flow and cause greater difficulties in treatment due to the reduced regenerative capabilities of the body. As a result of taking hormones muscles and skin become atrophic changes. Thinning and dry skin are particularly susceptible to trauma. Trophic ulcers in systemic connective tissue diseases often have no specific signs. Indicate systemic disease can atypical localization (thighs, buttocks, torso, upper extremity, head, mucosa of the oral cavity) wound, long for ulcers, with no tendency to regenerate, the big help in diagnostics renders the identification of syndromes, evidence of systemic autoimmune lesions of organs and tissues (polyarthritis, polyserositis, damage internal organs).
Purpose: description of the case of the treatment of the patient with Sjogren disease.
Materials and methods. In this report a clinical case of treatment of ulcers of the tibia on the background of long-term hormonal therapy. Patient more than 20 years of suffering from Sjogren's disease. Diagnosis of Sjogren’s disease (chronic, moderate activity (II) expressed stage), dry keratoconjunctivitis, parenchymatous parotitis, xerostomia, Raynaud's Syndrome, trophic ulcer of left tibia and varicose disease of the lower extremities, 2.
Sjogren’s disease - a systemic autoimmune disease characterized by involvement of exocrine glands, mainly salivary and lacrimal, with the gradual development of secretory failure, combined with various systemic manifestations. Local treatment of trophic ulcers took place against the background therapy of the underlying disease. In the first stage for cleansing the surface of trophic ulcers used for the contact controlled cryodestruction was carried out hydropressing treatment of the wound. The result - on the 5th day the wound was completely cleansed from necrotic tissue. Further, the local treatment consisted in the creation of optimal conditions for regeneration. After 4 weeks the wound is almost completely epithelization.
Conclusions. When Sjogren's disease treatment of ulcerative defects of the skin of the lower extremities takes place on the background of long-term hormonal medications. An important condition for wound healing is to decrease the dose of hormones to the minimum necessary. In this clinical observation in local treatment was applied the technique of contact controlled cryodestruction of pathological tissues on the surface of the ulcer.
5
Aquino, Terese Monette, and Maria Jasmin Jamora. "Primary Idiopathic Complex Aphthosis: Diagnosis and Successful Treatment with Montelukast in a 44-Year-Old Filipino Female." Case Reports in Dermatology 12, no. 1 (February 4, 2020): 12–18. http://dx.doi.org/10.1159/000505475.
Full textAbstract:
Recurrent aphthous stomatitis (RAS) is an oral condition characterized by frequent attacks of painful oral ulcers. Complex aphthosis (CA) is a severe form of RAS described as the almost constant presence of ≥3 oral ulcers with or without genital aphthosis. Management of primary CA varies, but most patients warrant the use of systemic agents. Because of prolonged treatment, it is preferred to use systemic medications with the least side effects. Herein, we present a case of a primary idiopathic CA. Workup and examination were done to exclude Adamantiades-Behçet’s disease and other diseases. The patient was shifted to montelukast after poor tolerance to colchicine. Favorable control of CA was noted during the 5-month follow-up period while the patient was on montelukast.
6
Agnihotri, Archna, Antervir Kaur, and Rosy Arora. "Oral Ulceration and Indian Herbs: A Scoping Review." Dental Journal of Advance Studies 8, no. 03 (August 30, 2020): 071–79. http://dx.doi.org/10.1055/s-0040-1716316.
Full textAbstract:
AbstractOral ulcers are one of the most prevalent oral mucosal diseases. The etiology of oral mucosal ulcers still has to be discerned as a variety of precipitating factors and causes have been implicated. Unless associated with some underlying systemic component, the condition generally takes 10 to 14 days to resolve, sometimes to recur soon. During the active disease phase, it affects eating, drinking and swallowing, thus affecting the quality of life. The treatment is generally symptomatic and is limited to the use of analgesics, antibiotics and topical application of steroids. The use of these over-the-counter drugs can sometimes lead to severe adverse effects. Herbal medicaments provide a safer and efficacious alternative to synthetic drugs. This article aims to review the most commonly used herbal medicines and investigate their efficacy in treating oral ulcers.
7
Kalogirou, Eleni-Marina, and Alexandra Sklavounou. "Is Dental Implantation Indicated in Patients with Oral Mucosal Diseases." Balkan Journal of Dental Medicine 21, no. 2 (July 26, 2017): 83–92. http://dx.doi.org/10.1515/bjdm-2017-0013.
Full textAbstract:
Summary Background/Aim: Dental implants are a reliable treatment choice for rehabilitation of healthy patients as well as subjects with several systemic conditions. Patients with oral mucosal diseases often exhibit oral mucosal fragility and dryness, erosions, blisters, ulcers or microstomia that complicate the use of removable dentures and emphasize the need for dental implants. The aim of the current study is to review the pertinent literature regarding the dental implantation prospects for patients with oral mucosal diseases. Material and Method: The English literature was searched through PubMed and Google Scholar electronic databases with key words: dental implants, oral mucosal diseases, oral lichen planus (OLP), epidermolysis bullosa (EB), Sjögren’s syndrome (SS), cicatricial pemphigoid, bullous pemphigoid, pemphigus vulgaris, scleroderma/systemic sclerosis, lupus erythematosus, leukoplakia, oral potentially malignant disorders, oral premalignant lesions, oral cancer and oral squamous cell carcinoma (SCC). Results: Literature review revealed dental implantation in patients with OLP (14 articles), EB (11 articles), pemphigus vulgaris (1 article), SS (14 articles), systemic sclerosis (11 articles), systemic lupus erythematosus (3 articles) and oral SCC development associated with leukoplakia (5 articles). No articles regarding dental implants in patients with pemphigoid or leukoplakia without SCC development were identified. Most articles were case-reports, while only a few retrospective, prospective or observational studies were identified. Conclusions: Dental implants represent an acceptable treatment option with a high success rate in patients with chronic mucocutaneous and autoimmune diseases with oral manifestations, such as OLP, SS, EB and systemic sclerosis. Patients with oral possibly malignant disorders should be closely monitored to rule out the development of periimplant malignancy. Further studies with long follow-up, clinical and radiographic dental data are required to predict with accuracy the outcome of dental implants in patients with oral mucosal diseases.
8
Gemaque, Karina, Gustavo Giacomelli Nascimento, José Luiz Cintra Junqueira, Vera Cavalcanti de Araújo, and Cristiane Furuse. "Prevalence of Oral Lesions in Hospitalized Patients with Infectious Diseases in Northern Brazil." Scientific World Journal 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/586075.
Full textAbstract:
The aim of this study was to assess the prevalence of oral lesions in infectious-contagious diseases patients being treated in the University Hospital of the Federal University of Pará, northern Brazil. One hundred seven patients with infectious diseases were clinically investigated for oral lesions at the University Hospital of Pará, northern Brazil. From total sample, most patients were men (65.7%) with a mean age of 45.4 years. About prevalence of systemic diseases, tuberculosis was the most frequent illness, followed by AIDS, hepatitis types B and C, leishmaniasis, and meningitis. Analyzing oral manifestations, periodontal diseases and candidiasis were the most prevalent diseases in both genders, followed by recurrent aphthous ulcers, saburral tongue, simplex herpes, and squamous cell carcinoma. Of all 107 patients, only 10 males and 6 females did not present any oral manifestation. There was no statistical difference between genders with any systemic condition (P>0.05). The great prevalence of oral manifestations in hospitalized patients with systemic disorder emphasizes the need of integral dental care in this context, aiming at a multidisciplinary approach of patients. Therefore, presence of some oral conditions, such as candidiasis, should be an alert to different systemic conditions, once in assistance with physicians; dentists can influence the early diagnosis and treatment.
9
Hasanah, Dian. "Behçet's Disease with Multiorgan Infection: Alternative Treatment to Systemic Immunosuppressants." Indonesian Journal of Rheumatology 12, no. 2 (February 17, 2021): 285. http://dx.doi.org/10.37275/ijr.v12i2.122.
Full textAbstract:
A B S T R A C T
Background. Behçet's disease is a rare systemic autoimmune vasculitis. The presence of infection makes it difficult to manage. Case. Ms. X, 19 years old, complained of mouth and genitalia ulcers and joints pain. She had typhoid fever two months before; and a week after recovery, she experienced reddish skin lesions on her legs. Her condition was weak and the pain visual analog score (VAS) was 9/10. Multiple oral ulcers were found in her oral cavity and vulva. Her lungs were hypersonor. There were hyperpigmented maculae in her lower extremities. Her ankle joints were painful in passive and active movements. Blood leukocytes: 13,210/µl, urine leukocytes: 20-23/hpf, ANA, anti-dsDNA and Pathergy tests were negative. The diagnosis of Behçet's disease was based on multiple oral and genital ulcers, history of erythema nodosum and arthritis. The patient was treated with topical triamcinolone. Joint ulcers and pain worsened; so that intravenous methylprednisolone was administer. Two days later, the patient had cough and oxygen desaturation. Chest X-ray showed emphysematous lungs and pneumonia. Methylprednisolone was stopped, ceftriaxone and levofloxacin were given, treatment for ulcers and arthritis was replaced with colchicine and rebamipide. Sucralfate is given for gargle and applied to the genital ulcers. On the seventh day, the ulcers were greatly reduced, joint pain resolved, cough subsided and VAS became 2/10. On the twelfth day, the chest X-ray was normal and ulcers were healed, ankle pain was suffered again accompanied by swelling. The patient was treated with methylprednisolone and azathioprine. Discussion. Treatment for this disease is immunosuppressants. In severe conditions with infection, colchicine can be an alternative treatment. Adjuvant treatment are rebamipide and/or sucralfate. Emphysematous lungs can be caused by alpha-1 antitrypsin deficiency or pulmonary vasculitis, which can be manifested in autoimmune diseases. Emphysematous lungs, leads us to follow up on the development to other autoimmune disorders such as lupus. Conclusion. Behçet's disease with infection can be successfully managed with colchicine, rebamipide and sucralfate.
10
Schmalz, Gerhard, Susann Patschan, Daniel Patschan, and Dirk Ziebolz. "Oral-Health-Related Quality of Life in Adult Patients with Rheumatic Diseases—A Systematic Review." Journal of Clinical Medicine 9, no. 4 (April 19, 2020): 1172. http://dx.doi.org/10.3390/jcm9041172.
Full textAbstract:
Objectives: The aim of this systematic review was to assess the oral-health-related quality of life (OHRQoL) of adult patients with rheumatic diseases. Material and Methods: A systematic literature search was performed, including clinical studies on adults (aged at least 18 years) with a verified diagnosis of rheumatic disease. Results: 26 out of 41 clinical studies including rheumatoid arthritis (RA, seven studies), systemic sclerosis (SSc, five), Sjögren syndrome (SS, eight), Behcet disease (BD, four), systemic lupus erythematosus (SLE, one) and ankylosing spondylitis (AS, one) were found. In 15 studies, a healthy control group was recruited. The short form of the Oral Health Impact Profile (OHIP 14) was most frequently applied. The majority of studies (14/15) reported worse OHRQoL in patients with rheumatic disease compared to healthy individuals. In particular, patients with SS (salivary flow and composition) or BD (oral ulcers) showed a relation between OHRQoL and disease-specific oral manifestations. Most studies investigating subscales of OHRQoL (5/6) found the subscale physical disability to be predominantly affected in patients with rheumatic diseases. About half of the studies reported impaired psychosocial aspects. Conclusion: Patients with rheumatic diseases exhibit reduced OHRQoL, especially in diseases with oral manifestations like SS and BD. Physical affections due to oral diseases and psychosocial impairments caused by disease-related parameters must be recognized within patient-centered dental care.
11
Alaya, Z. alaya. "Mucocutaneous involvement in behçet’s disease." Journal of Clinical Research and Reports 5, no. 5 (November 21, 2020): 01–03. http://dx.doi.org/10.31579/2690-1919/0129.
Full textAbstract:
Behçet's disease is a chronic inflammatory disease characterized by its clinical polymorphism associating mucocutaneous involvement to systemic manifestations. The mucocutaneous lesions are considered the hallmark of the disease, being the most common symptoms presenting at the onset of disease. Our objective was to determine the characteristics of this skin involvement during Behçet's disease. We conducted a descriptive study over a period of 30 years, having collected all patients with Behçet's disease. These were 98 patients. A male predominance was observed in our studied population with a Sex Ratio of 2.5. The mean age at diagnosis was 34 years. Mucocutaneous involvement was observed in all patients. Oral aphthosis was constant and genital ulcers, were observed in 81 cases. The other mucocutaneous manifestations were: pseudofolliculitis (61 cases), erythema nodosum (7 cases), skin ulcers (4 cases), acneiform lesions (2 cases), perianal ulcers (1 case), skin ulceration (1 case) and erythema multiforme. (1 case). All of our patients were treated with colchicine. Corticosteroids and non-steroidal anti-inflammatory drugs were each indicated in one case for resistant forms.
12
Budanur, Damla Tuncer, Merve Şirin, Elif Sepet, Meral Ünür, Mine Güllüoğlu, Mustafa Serdar Cantez, and Özlem Durmaz Uğurcan. "Orofacial Crohn’s disease: a Case Report." Balkan Journal of Dental Medicine 21, no. 2 (July 26, 2017): 123–26. http://dx.doi.org/10.1515/bjdm-2017-0021.
Full textAbstract:
Summary Background: Crohn’s disease (CD) and ulcerative colitis (UC) are the two major relapsing conditions of inflammatory bowel diseases. Case Report: A case of Crohn’s disease with orofacial manifestations in a 10 year old girl is described. She had suffered from fever, dysphagia, arthralgia, painful recurrent ulcers of the oral mucosa and swelling of the lower lip lasting over 6 weeks. Clinical examination and the punch biopsy from the buccal mucosa revealed major recurrent aphthous ulcerations. A partial regression and significant relief of lesions were achieved two weeks after the treatment, but the patient suffered from abdominal pain, irregular bowel movements, arthritis, multiple hyperplastic and swollen mucosal folds, after 3 months. The patient was referred to a pediatric gastroenterologist. Esophagogastroduodenoscopy showed pyloric ulcer formation. Abdominal ultrasound showed increased thickening of the ileal wall with multiple enlarged lympadenopathies in the periileal region. Colonoscopy images showed deep ulcers with surrounding erythema. The histopathological examination of biopsies from the terminal ileum and the colon showed basal plasmacytosis, minimal crypt distortions and aphthous ulcerations. The diagnosis of Orofacial Crohn’s disease was made. Exclusive enteral nutrition for 8 weeks, followed by azathiopurine treatment was started with an excellent clinical response on abdominal and oral symptoms. Conclusion: Diagnosis of the disease by dentists and other clinicians through the evaluation of oral clinical findings is very rare. Mucocutaneous and granulomatous lesions of the oral cavity should alert the clinician to pursue an underlying systemic cause. Early communication with a gastroenterologist can help early diagnosis of Crohn’s disease for better patient management and prognosis.
13
Robinett, Kathryn S., Bethany Weiler, and Avelino C. Verceles. "Invasive Aspergillosis Masquerading as Catastrophic Antiphospholipid Syndrome." American Journal of Critical Care 22, no. 5 (September 1, 2013): 448–51. http://dx.doi.org/10.4037/ajcc2013659.
Full textAbstract:
A 25-year-old woman with a history of systemic lupus erythematosus who was taking steroids came to the hospital because of vague signs and symptoms of weight loss, constipation, and oral ulcers. Multiorgan dysfunction developed, and catastrophic antiphospholipid syndrome was suspected. She was treated with an intravenous infusion of heparin, but she experienced a subdural hemorrhage and died on day 10 of the hospitalization. An autopsy revealed disseminated invasive aspergillosis. This case illustrates that invasive aspergillosis is a frequently missed diagnosis and should be part of the differential diagnosis for any patient who is immunosuppressed, including patients with autoimmune diseases such as systemic lupus erythematosus.
14
Ge, Shuyun, Lin Liu, Qi Zhou, Binbin Lou, Zengtong Zhou, Jianing Lou, and Yuan Fan. "Prevalence of and related risk factors in oral mucosa diseases among residents in the Baoshan District of Shanghai, China." PeerJ 8 (February 24, 2020): e8644. http://dx.doi.org/10.7717/peerj.8644.
Full textAbstract:
Background Oral mucosal diseases (OMDs) encompass a variety of different types of diseases. Our aim was to evaluate the prevalence and related risk factors of OMDs among residents in the Baoshan District of Shanghai, China, and provide a scientific basis for prevention and control strategies. Methods A sample of 653 residents aged 17 to 92 years from the Baoshan community was investigated in 2014. Each resident was surveyed by questionnaire to evaluate their oral mucosa and oral mucosa examinations were conducted. We followed up with 607 residents in 2018. All data were statistically analyzed using the SPSS 25.0 software package (Chicago, IL, USA) at the general population, gender and age levels. A X2 test was used to compare rates of risk factors and logistic regression analysis was used to detect the correlation between disease and risk factors. Results The prevalence rate of OMDs was found to be 9.19%–9.56% (2014–2018). The most common OMDs were atrophic glossitis (1.84%), recurrent aphthous ulcer (RAU, 1.68%), burning mouth syndrome (BMS, 1.38%), oral lichen planus (OLP, 1.23%) and traumatic ulcers (1.23%). The prevalence of RAU and BMS in different age groups was significantly different. Tobacco and alcohol use and psychological factors in the OMDs group were higher than the no-OMDs group. Systemic diseases including diabetes mellitus (DM) was significantly relevant to OLP. Conclusion Age, tobacco and alcohol use, and psychological factor correlated strongly with the occurrence and development of OMDs, and they should be the focus of primary prevention. General epidemiological studies suggested that OLP was closely related to DM.
15
Alese, Olatunji B., and David O. Irabor. "Pyoderma gangrenosum and ulcerative colitis in the tropics." Revista da Sociedade Brasileira de Medicina Tropical 41, no. 6 (December 2008): 664–67. http://dx.doi.org/10.1590/s0037-86822008000600020.
Full textAbstract:
Pyoderma gangrenosum is a rare inflammatory skin condition, characterized by progressive and recurrent skin ulceration. There may be rapidly enlarging, painful ulcers with undermined edges and a necrotic, hemorrhagic base. Disorders classically associated with pyoderma gangrenosum include rheumatoid arthritis, inflammatory bowel disease, paraproteinemia and myeloproliferative disorders. There have been some reports of the occurrence of pyoderma gangrenosum in Africa, and in Nigeria, but only one specifically reported pyoderma gangrenosum in association with ulcerative colitis. We report on a 45-year-old man who presented with pyoderma gangrenosum associated with ulcerative colitis; the second report in Nigeria. The skin lesions were managed with daily honey wound dressings. Oral dapsone and prednisolone were started. The frequency of the bloody diarrhea decreased, and was completely resolved by the second week after admission. The ulcers also showed accelerated healing. The goal of therapy is directed towards the associated systemic disorder, if present.
16
Aguiar, Marta Gontijo, Aline Márcia Machado Pereira, Ana Paula Fernandes, and Lucas Antonio Miranda Ferreira. "Reductions in Skin and Systemic Parasite Burdens as a Combined Effect of Topical Paromomycin and Oral Miltefosine Treatment of Mice Experimentally Infected with Leishmania (Leishmania) amazonensis." Antimicrobial Agents and Chemotherapy 54, no. 11 (August 16, 2010): 4699–704. http://dx.doi.org/10.1128/aac.00809-10.
Full textAbstract:
ABSTRACT This study aimed to investigate the activity of a combination of topical paromomycin gel and oral miltefosine for the treatment of experimental cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis. The efficacy of the combination, evaluated by measuring lesion size and parasite burden in the skin and spleen, was assessed in BALB/c mice infected by L. (L.) amazonensis. The miltefosine was administered orally at 10 mg/kg of body weight/day for 10 days, while 10% paromomycin gel was applied topically twice a day for 20 days. Treatment of the experimentally infected animals with a topical paromomycin-oral miltefosine combination induced a statistically significant reduction in lesion size and parasite burden in the skin and spleen, with complete healing of ulcers, compared with those treated with a placebo group. A combination of topical paromomycin gel and oral miltefosine provided enhanced efficacy in the treatment of L. (L.) amazonensis-infected mice, showing activity higher than that observed for the monotherapeutic regimens.
17
Sumartini Dewi, Tasya Aniza Yusuf, and Fahrizal Yanuar. "Idiopathic CD4+ Lymphocytopenia in Overlap Syndrome (Systemic Sclerosis with Dermatopolimyositis)." Indonesian Journal of Rheumatology 13, no. 1 (August 10, 2021): 486–91. http://dx.doi.org/10.37275/ijr.v13i1.165.
Full textAbstract:
Background : Idiopathic CD4 T cell lymphocytopenia (ICL) is a rare syndrome with varied clinical manifestation, characterized with lymphopenia and decreased in CD4 level without HIV infection or other possible cause of immunodeficiency state. Autoimmune diseases might be a clinical manifestation of ICL. However, it is not known whether ICL triggered an autoimmune diseases, or it is a complication of said diseases.
Objective : Awareness of ICL in patient with known autoimmune diseases whom admitted to the hospital for severe infection.
Methods : This case report showed a 24-years old woman with prolonged fever since 4 moths ago. It was accompanied with oral ulcers, skin rash in face and trunks, and weakness of lower extremities. She was diagnosed with systemic sclerosis since 2016 and routinely came to rheumatology outpatient clinic in Hasan Sadikin Hospital but stopped coming for past 4 months since pandemic. Her current medication was only 4 mg of methylprednisolone.
Results : She had high temperature (38.5 degree Celsius) and tachycardia. Physical examination revealed a single lymphadenopathy at neck. Raynaud phenomenon, calcinosis, and sclerodactyly was found in lower extremities. Dermatomyositis was diagnosed based by heliotropic skin rash. Laboratory tests showed leukopenia, absolute lymphocyte count 135.2 cell/mm3, absolute CD4 39/uL, CK level of 3296 and nonreactive anti-HIV. The patient underwent empirical antibiotic treatment, but unfortunately passed away.
Conclusion : ICL is a rare case, following an infection, autoimmune diseases, or unspecified malignancy. Clinician’s awareness toward ICL could prevent fatal opportunistic infection which often happens to patients with immunodeficiency state.
18
Ewan, Victoria, and Konrad Staines. "Diagnosis and management of oral mucosal lesions in older people: a review." Reviews in Clinical Gerontology 18, no. 2 (May 2008): 115–28. http://dx.doi.org/10.1017/s0959259809002767.
Full textAbstract:
Oral mucosal lesions occur frequently in older people and are important as they may reduce quality of life, represent pre-malignant change or indicate systemic disease. The commonest mucosal lesions in adults are denture-related lesions such as stomatitis, angular cheilitis, ulcers and hyperplasia, and occur in 8.4% of the adult population. In the hospital setting, oral mucosal lesions may lead to malnutrition, slow rehabilitation and recovery from illness, and adversely affect quality of life. The two major risk factors associated with oral lesions are denture use and smoking, and frequently older people have been exposed to both of these. Commonly used drugs such as antihypertensives, antidepressants and antibiotics may have oral mucosal side-effects, and polypharmacy may worsen these. Decreased awareness of changes in the oral mucosa, or inability to raise concerns due to dementia, delirium, social isolation, or difficulty accessing dental care may further compound the problem. Hospital admission could represent an opportunity to intervene, but oral mucosal lesions, and indeed oral hygiene, are areas which can be overlooked by doctors. This article is intended to highlight common or important oral mucosal diseases and increase awareness of these conditions for the practising hospital or community geriatrician.
19
Al Ghafri, Aadil, and Humaid Al Wahshi. "Demographic features and clinical aspects of Behçet’s disease in Omani patients." Rheumatology Practice and Research 3 (January 1, 2018): 205990211774222. http://dx.doi.org/10.1177/2059902117742226.
Full textAbstract:
Objectives: Behçet’s disease is a chronic, relapsing, multisystem vasculitis of unknown etiology. Few reports support the hypothesis that Behçet’s disease has a primarily hereditary basis. It complicated diversified clinical features predominantly involving oral and genital ulcers, and ocular and cutaneous lesions. The clinical features of this disease have been described to be different according to geographical areas and gender. The objective of the study is to explore the demographic features and clinical aspects of Behçet’s disease in Omani patients and to compare the results with those of various reports in the region. Methods and results: In total, 56 Behçet’s disease patients were recruited, and clinical data parameters were recorded including age, sex, age at diagnosis, duration of symptoms till diagnosis, disease characteristics such as oral and genital ulcers, ocular manifestations, the presence of arthritis, and cutaneous lesions such as papulopustular lesions and erythema nodosum. Furthermore, other systemic involvement was studied including gastrointestinal, neurological, renal, and vascular manifestations. Laboratory tests of Behçet’s disease and treatment used were recorded in each patient. The onset was between 6 and 74 years with a male predominance. Oral ulcers were the most common manifestation, followed by genital ulcers, ocular lesions, and arthritis. Vascular lesions and gastrointestinal manifestations were less common. Cutaneous manifestations were rare in patients with Behçet’s disease. The frequency of neurological involvement was significantly high. There were no reported cardiac or urogenital manifestations. Conclusion: Behçet’s disease’s demographic features and clinical aspects in Omani patients showed quite significant geographical and gender differences which are comparable to other data in the area.
20
Chrismawaty, Bernadeta Esti, and Goeno Subagyo. "Ulkus Aftosa Kompleks Manifestasi Penyakit Crohn." Majalah Kedokteran Gigi Indonesia 19, no. 1 (June 30, 2012): 33. http://dx.doi.org/10.22146/majkedgiind.15651.
Full textAbstract:
Latar Belakang: Ulkus aftosa kompleks mengacu pada ulkus mulut kronis berkaitan dengan gangguan sistemik. Kondisi tersebut, selain menimbulkan rasa sakit dan gangguan fungsi, dapat memperburuk kualitas hidup penderitanya. Tujuan: penulisan ini bertujuan untuk melaporkan keterkaitan antara ulkus aftosa kompleks dengan gangguan gastrointestinal, yaitu penyakit crohn. Kasus dan penanganannya: laki-laki 73 tahun mengeluhkan nyeri mulut sejak 3 bulan lalu, yang disertai dengan perut sebah, kembung dan terkadang nyeri ringan disertai dengan sakit kepala. Saat pemeriksaan, tampak adanya ulkus dengan dasar bergranuler, tepi sedikit meninggi dan tertutup lapisan putih pada mukosa lipatan mukobukal, pipi, dasar mulut dan palatum. Permukaan mukosa bibir dan pipi memberikan gambaran seperti batu bata (cobblestoning). Mengacu pada gejala dan temuan klinis, ditegakkan diagnosis kerja ulkus aftosa kompleks manifestasi gangguan gastrointestinal, susprk penyakit crohn. Terapi awal berupa kombinasi spiramycin-metronidazole, methyl-prednisolone, parasetamol dan larutan kumur perhidrol. Satu minggu kemudian, tampak adanya perbaikan lesi dan aktifitas fungsional. Berdasarkan pemerikasaan dari poli penyakit dalam Rumah Sakit Umum Sardjito (RSS), pasien mendapatkan medikasi lanzoprazole, ulsidex dan enzyplex. Terapi lanjutan berupa methyl-prednisolone dengan dosis tapering, anti jamur topical nistatin untuk mencegah infeksi ikutan dan larutan kumur yeng mengandung Benzydamine HCI untuk mengurangi nyeri. Kesimpulan: Ulkus mulut manifestasi penyakit Chohn mempunyai karakteristik unik dan dapat dibedakan dari ulkus mulut kronis lainnya. Dalam penegakan diagnosis ulkus aftosa kompleks, identifikasi etiologi gangguan sistemik yang tepat akan sangat membantu dalam menetapkan perawatan lesi mulut yang sesuai. Background: complex aphthous refers to chronic oral ulceration, which is related to systemic diseases. This condition can cause oral discomfort, alter the normal oral function anf eventually can decrease the quality of life. Purpose: this paper is intended to report the relationship between complex aphthous with gastrointestinal disorder, in particular crohn’s disease. Case and management: A73 year old man complaint a chronic sore mouth since 3 months ago. Abdominal discomfort, mild indigestion and headache occur accompanied by oral symptoms. Clinically, there were multiple ulcers with granular base, slightindurate border covered with white thick layers at mucobuccal fold, buccal, floor of the mouth and palate mucosa. Labial and buccal mucosa demonstrates a cobblestoning appearance. According to systemic symptoms and oral findings, complex aphthous as manifestation of gastrointestinal diseases, specifically suspected to Crohn’s diseases, is accepted as working diagnosis. Spiramycin combined with Metronidazole, Methyl-prednisolone, Paracetamol and perhidrol mouthwash were given as initial therapy. One week later, it seems some improvement on oral lesion and oral functional activity. From internal Medicine Clinic, Sardjito General Hospital, patient received Lanzoprazole, Ulsidex and Enzyplex. Tapering doses of methyl-prednisolone and oral fungal topical Nystatin for prevention from secondary infection were given as subsequent therapy. Benzydamine mouthwash was given for alleviate sore mouth. Conclusion: Complexs apthous ulcers as manifestation of crohn’s disease have a unique characteristic and quite discriminate to other chronic oral ulceration. In establishing the diagnosis of complex aphthous., the identification of proper etiology would help in determining the appropriate management of the oral lesion.
21
Vineetha, Mary, Seena Palakkal, Lissy Skaria, Naveena Jose, Dhiya Philomina, and Anila Nithin. "Autoinflammatory syndromes: A review." Journal of Skin and Sexually Transmitted Diseases 2 (April 17, 2020): 5–12. http://dx.doi.org/10.25259/jsstd_24_2019.
Full textAbstract:
Autoinflammatory syndromes (AIS) are disorders of innate immunity which present with recurrent episodes of fever and skin lesions, such as urticaria, pustules, maculopapular rash, oral ulcers, generalized pustular psoriasis, or pyoderma gangrenosum-like lesions. The different entities that come under AIS are familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinemia D with periodic fever syndrome, and cryopyrin-associated periodic syndromes. Many new entities are also described. As many of them present with skin lesions, dermatologists should be aware of myriad of clinical features associated with these disorders. Childhood onset, positive family history, and elevated laboratory markers of systemic inflammation during acute episodes are the clues to diagnosis. Infections, connective tissue diseases, and malignancies should be excluded before diagnosing AIS.
22
Younes, Samia, Yosra Cherif, Narjes Mokni, Olfa Berriche, Baha Zantour, Amel Boughammoura, Mahbouba Frih-Ayed, Saida Jerbi, and Mohamed Habib Sfar. "Cerebral Aneurysms: A Rare Feature of Behçet's Disease—A Case Report and Review of the Literature." Case Reports in Neurological Medicine 2013 (2013): 1–6. http://dx.doi.org/10.1155/2013/812158.
Full textAbstract:
Behçet's disease (BD) is a multisystem vascular inflammatory disease with several clinical manifestations. Intracranial aneurysms are an extremely rare but nevertheless severe complication of BD. We report a case of a 44-year-old man. The diagnosis of BD was made based on the presence of recurrent oral aphthous ulcers and positive human leukocyte antigen (HLA-) B51 in the absence of evidence of other diseases. MRI showed an ancient ischemic right capsulolenticular lesion, subacute white matter hypersignals of the left capsule lenticular region, and multiple arterial aneurysms. The patient underwent two-month systemic high-dose corticosteroids and immunosuppressive therapy associated with severe neurological deficiency upon admission and severe impairment upon discharge. A thorough review of the literature showed 20 case reports of intracranial aneurysms in BD.
23
Kaleda, M. I., I. P. Nikishina, S. O. Salugina, E. S. Fedorov, and E. V. Nikolaeva. "MACROPHAGE ACTIVATION SYNDROME IN RHEUMATIC DISEASES IN CHILDREN: A RETROSPECTIVE STUDY." Pediatria. Journal named after G.N. Speransky 100, no. 5 (October 11, 2021): 53–61. http://dx.doi.org/10.24110/0031-403x-2021-100-5-53-61.
Full textAbstract:
Macrophage activation syndrome (MAS) is a rare life-threatening complication of rheumatic diseases (RD) that requires early recognition and adequate immediate treatment. Objective of the study: to identify the features of onset of RD in patients who developed MAS, the clinical and laboratory characteristics of the MAS, possible trigger factors and the timing of development. Materials and methods of research: 57 patients (20 boys and 37 girls) with RD who developed MAS were included in a retrospective continuous non-randomized study: 36 (63%) with systemic juvenile idiopathic arthritis (sJIA), 19 (33%) with Systemic lupus erythematosus (SLE), 1 (2%) – with juvenile dermatomyositis (JDM), one (2%) – with overlapping syndrome. Results: in the structure of patients with sJIA, patients with a history of MAS accounted for 28%, among patients with SLE – 7,6%. The median age at the time of sJIA debut in the study group was 2,6 years [1,5; 5,75], patients with SLE – 11,8 years [8,6; 13,95]. The ratio of boys and girls in the study group was 1:1,85. 70 MAS episodes were recorded: 48 – with sJIA, 20 – with SLE, one episode each for JDM and crossover syndrome. A single episode of MAS at the onset had 22% of patients with sJIA, 47% – with SLE, MAS during the course of the disease – 55% and 47%, repeated episodes of MAS – 25% and 5% of patients, respectively. Clinical manifestations of MAS included fever in 91% of children, hepatomegaly in 54%, pericarditis in 51%, skin lesions in 68%, CNS damage in 44%, lung damage in 33%, hyperferritinemia in 96%, thrombocytopenia – in 79%, increased aminotransferases – in 89%, hypertriglyceridemia – in 53%. Patients with sJIA and MAS had statistically significantly earlier onset (p=0,047), a greater number of systemic manifestations (p=0,012), a typical exanthema (p<0,0001), and a smaller number of active joints (p=0,041). 83% of them had episodes of MAS before the initiation of therapy with biological disease-modifying antirheumatic drugs (bDMARDs). There was no statistically significant relationship between the development of MAS with the use of bDMARDs with a clear positive relationship with the violation of the therapy regimen. 19% of patients with sJIA and MAS had a history of infusion reaction to tocilizumab, 8% later had interstitial lung damage. Patients with SLE and MAS at the onset were statistically significantly more likely to have serositis (p=0,0028), ulcers of the oral mucosa (p<0,0001), neuropsychiatric disorders (p=0,0024), positive Coombs' test (p=0,026). All patients received glucocorticoid therapy; experience with the use of GIBP in the study group was limited. Conclusion: MAS in children develops more often with sJIA; the dominant provoking factor is the activity of the underlying disease. The overwhelming majority of patients developed MAS during the course of the disease, less often at the onset. Patients with a history of MAS with sJIA are characterized by an earlier age of onset, a predominance of systemic manifestations, the need for early administration of bDMARDs therapy, and a tendency to infusion reaction to tocilizumab. Against the background of bDMARDs, a subclinical course of MAS with the absence of fever is possible. The risk of developing MAS along with SLE is higher in patients with onset of serositis, ulcers of the oral mucosa, neuropsychiatric disorders, and a positive Coombs' test. MAS cases were detected with high SLE activity at the onset, violation of the treatment protocol.
24
Kamath, Pragathi, Bela Verma, and Tejasi Sawant. "A rare case of childhood polyarteritis nodosa successfully treated with etanercept." International Journal of Research in Medical Sciences 7, no. 7 (June 28, 2019): 2837. http://dx.doi.org/10.18203/2320-6012.ijrms20192930.
Full textAbstract:
Childhood Polyarteritis Nodosa (CPAN) a rare and often fatal disease tends to be more common in individuals of Asian descent. Previously it was referred to as Infantile PAN. Polyarteritis Nodosa (PAN) is a systemic autoimmune vasculitis characterized by necrotizing inflammatory lesions of the medium-sized and small muscular arteries, preferentially at vessel bifurcations, resulting in formation of microaneurysms, aneurysmal ruptures with hemorrhage, thrombosis and consequently organ ischemia or infarction. It usually appears in middle or older age without gender predilection. PAN shows variety of symptoms, including general symptoms, neurological, skin, renal and gastrointestinal involvement. In particular skin lesions characterized by multiple firm waxy papules, subcutaneous nodules, livedo reticularis, ulcers and gangrene are observed in 25%-60% of patients with PAN. The etiology of systemic vasculitis is yet unknown. However, dysregulation and/or enhanced expression of pro-inflammatory substances may be involved in pathogenesis of these diseases. Tumour necrosis factor (TNF) alpha is a pro-inflammatory cytokine produced primarily by cells of macrophage-monocyte lineage which may directly participate in vascular inflammation as well as in endothelial cell death via apoptosis. In addition, TNF-alpha may play a role in neutrophil priming inducing membrane expression of Proteinase-3 or Myeloperoxidase which are subsequently recognized by ANCA-associated vasculitis (AAV). Author report a case of 14 months old male child with complaints of fever, gangrenous changes of ear lobes, tip of nose and toes, seizures, altered sensorium and hypertension. Initially Injectable Methyl Prednisolone pulse therapy was started followed by oral Prednisolone. After initiation of Etanercept treatment, his symptoms improved dramatically. Sensorium improved, skin ulcers healed faster, and gangrenous changes were arrested, fever subsided and child started accepting oral feeds.
25
Anwar, Salman, Karen Holfeld, and Bhanu Prasad. "Peritoneal Dialysis Exit Site Pyoderma Gangrenosum: A Case Report." Case Reports in Nephrology and Dialysis 8, no. 3 (November 14, 2018): 239–45. http://dx.doi.org/10.1159/000493188.
Full textAbstract:
Background: Pyoderma gangrenosum (PG) is a rare, chronic inflammatory condition exhibiting mucopurulent or hemorrhagic exudates. The majority of cases are associated with inflammatory bowel disease, rheumatological diseases, and hematological malignancies. In the absence of typical serological markers and specific histopathological changes, the diagnosis is often clinical. Being rare, it is frequently misdiagnosed, which leads to a delay in instituting appropriate therapy. Case Presentation: We present a 53-year-old male of Aboriginal descent with end-stage renal disease due to diabetes who underwent insertion of a peritoneal dialysis (PD) catheter. Five weeks after PD catheter insertion, he started to notice a painful ulcer surrounded by a bed of erythema. The lesion eventually progressed to a purulent, hemorrhagic ulcer surrounded by a raised, irregular, violaceous border along the entirety of the PD catheter tunnel. There was no history of underlying systemic diseases commonly associated with PG. The catheter was removed, and an elliptical biopsy was taken, which ruled out infection, malignancy, and vasculitis. The changes were felt to be consistent with PG. The patient underwent treatment initially with topical corticosteroids, followed by oral prednisone, which unfortunately worsened his diabetic control; due to this, he was transitioned to cyclosporine, with complete resolution. Conclusions: Lesions at the PD catheter exit site are usually treated for infections. However, for ulcers that are painful, rapidly expanding, nonhealing, and unresponsive to antibiotics, PG should be considered as a differential diagnosis. This is the first reported case of PG occurring at the exit site of a PD catheter.
26
Seixas, Gabriela Fleury, Aline Fernanda Spadrizani, Danielle Gregorio, Marcelo Lupion Poleti, and Thais Maria Freire Fernandes. "Seropositive HIV diagnosis after oral histoplasmosis: the importance of multi-professional care in health." Research, Society and Development 9, no. 9 (September 4, 2020): e716997839. http://dx.doi.org/10.33448/rsd-v9i9.7839.
Full textAbstract:
Histoplasmosis is a systemic fungal disease, which can manifest with extrapulmonary lesions. Oral lesions are rarely the first manifestation of late histoplasmosis and can represent an important process of immune imbalance. The objective of this work is to present a clinical case of Histoplasmosis with an oral manifestation of a patient who was unaware of her condition with the Human Immunodeficiency Virus (HIV). The patient's main complaint was a painful ulcer in the central region of the tongue present for two months, whose incisional biopsy resulted in the diagnosis of Histoplasmosis. Although referred for medical treatment with an infectologist, the patient had complications resulting from the disease and died after one month. This situation demonstrates the importance of multidisciplinary care in the prevention, diagnosis and treatment of diseases. The correct diagnosis and treatment can be decisive in the prognosis of patients and demonstrates the relevance of the dentist's knowledge about the various systemic diseases that present oral manifestations.
27
Akca, Ummusen Kaya, and Ezgi Deniz Batu. "SIMILARITIES AND DIFFERENCES BETWEEN FAMILIAL MEDITERRANEAN FEVER AND BEHÇET’S DISEASE." Central Asian Journal of Medical Hypotheses and Ethics 2, no. 1 (April 2, 2021): 43–50. http://dx.doi.org/10.47316/cajmhe.2021.2.1.07.
Full textAbstract:
Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease, mainly affecting populations originating from the Eastern Mediterranean region. Behçet’s Disease (BD) is grouped in polygenic autoinflammatory diseases. It is a systemic vasculitis that affects all types and sizes of blood vessels. The aim of this article is to shed light on similarities and differences between FMF and BD. BD is frequently reported along the ancient Silk Road, extending from the Far East to the Mediterranean basin. Several studies have searched for the association between FMF and BD. FMF is caused by mutations of the MEditerranean FeVer (MEFV) gene while an increased frequency of MEFV mutations is reported in BD patients. Although BD and FMF share some epidemiological and pathophysiological features, there are distinct clinical characteristics of these nosological entities. Mucocutaneous manifestations, especially recurrent oral ulcers, are the most common symptom in BD patients whereas fever accompanied by serosal inflammation is the main clinical presentation in FMF patients.
28
Yanko, N. V., L. F. Kaskova, I. Yu Vashchenko, S. Ch Novikova, and O. S. Pavlenkova. "ORAL MANIFESTATIONS OF VIRAL INFECTIONS IN CHILDREN." Ukrainian Dental Almanac, no. 3 (September 23, 2020): 69–74. http://dx.doi.org/10.31718/2409-0255.3.2020.11.
Full textAbstract:
Viral diseases with oral manifestations are common in the practice of pedodontist, however, sometimes their diagnosis is complicated due to the similar clinical manifestations. A huge number of viruses are present in oral cavity, especially from Herpesviridae family, however, the most of them are asymptomatic. Cold, systemic diseases and stress provoke the activation of viruses with different clinical manifestations. Therefore, a dentist can be the first who diagnoses not only herpetic gingivostomatitis, but also other viral diseases.
The aim of the article was to analyse the oral manifestations of viral diseases in children in order to optimize their diagnostics.
This article analyses clinical cases and reviews of diseases in English in Google database from 2011 to May 2020 (and earlier publications) by
Keywords:
«herpetic gingivostomatitis», «recurrent aphthous stomatitis», «oral manifestations of infectious mononucleosis», «herpetic angina», «oral manifestations of cytomegalovirus infection», «recurrent herpetic gingivostomatitis», «oral manifestations of varicella virus», «oral manifestations of herpes zoster», «roseola infantum», «herpangina», «hand, foot and mouth disease», «oral manifestations of measles», «rubella», «oral manifestations of papillomavirus», and «oral manifestations of human immunodeficiency virus».
Viruses which have oral manifestations were characterized by transmission. Mostly airborne viruses are represented by Herpesviridae family. The differential diagnosis of primary herpetic gingivostomatitis includes recurrent aphthous stomatitis which forms ulcers on non-keratinised oral mucosa without a vesicle phase. Recurrent herpetic infection doesn’t have difficulties in diagnostics, but could be complicated by erythema multiform with clear target lesions. Vesicles, erosions in oral cavity associated with vesicles on hear part of head help to distinguish chickenpox from herpetic infection. Compared to Herpes simplex virus infection, Herpes zoster has a longer duration, a more severe prodromal phase, unilateral vesicles and ulceration, with abrupt ending at the midline and postherpetic neuralgia. Roseola is characterized by small papules on skin and palate which appears when severe fever in prodromal period subsides and disappears after 1-2 days. Oral vesicles associated with foot and hand rush differentiate enterovirus stomatitis from chickenpox and roseola. The distribution of the lesions of herpangina (palate, tonsils) differentiates it from primary herpetic gingivostomatitis, which affects the gingivae.
Comparing with roseola and rubella, measles has a bigger size of rush and specific oral localization on buccal mucosa. Mild fever and skin rush which appears on face and extensor surfaces of body and extremities help to distinguish rubella from measles and roseola.
Viruses transmitted through biological liquids are represented in oral cavity by infectious mononucleosis and cytomegalovirus. The vesicles and ulcers on the tonsils and posterior pharynx in case of these infections can resemble herpetic stomatitis, but liver and spleen enlargement allows to exclude this diagnose; also cytomegalovirus erosions heal for long time. Cervical lymphoadenopathy differentiates them from herpetic angina. Laboratory diagnostics is based on detection of antibodies to virus or virus DNA in blood helps to make diagnosis of infectious mononucleosis and cytomegalovirus infections.
Viruses transmitted through direct contact with mucosa and biological liquids represented by human papillomavirus (HPV) and human immunodeficiency virus (HIV). HPV in oral cavity represent by benign epithelial hyperplasia which might persist and transform to malignant. Therefore, histological examination plays important role in diagnostics of HPV.
Oral manifestations such as candidiasis, herpes labialis, and aphthous stomatitis represent some of the first signs of HIV immunodeficiency. Oral lesions also associated with HIV in children are oral hairy leukoplakia, linear gingival erythema, necrotizing ulcerative gingivitis, and Kaposi’s sarcoma. Rapid necrotization and long-term healing of oral lesions help to suspect HIV and prescribe the blood test for the detection of antibodies to the virus.
Oral mucosa is often the first to be affected by viral infections. A thorough anamnesis and examination is the key to accurate diagnostics of the most oral viral lesions and their adequate treatment. Biopsy, examination of antibodies to the virus in the blood or polymeraze-chain reaction to the virus in the bioptate or blood are performed in case of diagnostic difficulties. Laboratory methods had to use more widely for the diagnostics of recurrent or unclear lesions of the oral mucosa in children.
29
Skikevych, M. G., and L. I. Voloshyna. "PECULIARITIES OF MANIFESTATION OF THE SKIN FORM OF LEISHMANIASIS OF MAXILLOFACIAL LOCALIZATION." Ukrainian Dental Almanac, no. 2 (June 26, 2020): 63–66. http://dx.doi.org/10.31718/2409-0255.2.2020.10.
Full textAbstract:
Leishmaniasis is a vector-borne disease in humans. Simple intracellular parasites cause the disease. Risk factors: socio-economic conditions, poverty. The disease is associated with malnutrition, with population displacement, with poor housing conditions, with a weak immune system, poor sanitary conditions, and lack of waste disposal. Up to 1 million new infections and up to 65,000 deaths from this disease occur annually. About 95% of cases of skin form disease occur in the countries of the American continent. Leishmaniasis occurs in Uzbekistan and Turkmenistan.
The carriers of this disease are female mosquitoes. In the mosquito, parasites are in flagellate form. The natural reservoirs of Leishmania can be around 70 species of animals and humans. Infection occurs through mosquito saliva. After a bite, the parasite invades human mononuclear phagocytes. There may be infection of a person in contact with ulcers and other types of damage. Veterinarians have noted a dramatically increasing number of cases of disease in domestic animals.
The following forms are clinically distinguished: cutaneous, mucocutaneous, diffuse cutaneous and visceral forms of leishmaniasis. After the disease develops, a stable immunity to this particular type of leishmaniasis develops.
Cutaneous leishmaniasis is the most common form. Ulcers form in open areas of the body. Typical places of localization: face, ears, knees, elbows. Some nodules may have a warty surface or resemble xanthomas, keloids. After healing of these ulcers, scars remain for life.
The nasopharynx, oral cavity, or nasal mucosa can be affected without destroying the nasal septum. For cutaneous leishmaniasis, the formation of an infectious granuloma is also characteristic.
Treatment of cutaneous leishmaniasis can be local or systemic, depending on the damage and pathogen. Local treatment is suitable for minor and uncomplicated lesions. Local treatment options: heat therapy, cryotherapy. Systemic therapy is used in patients with multiple extensive rashes.
Patient K. turned to the maxillofacial department. The patient came home to Ukraine for the purpose of diagnosis and treatment. The patient works in Poland at a construction site. According to the patient, several courses of treatment. The treatment had no result. The pharmacotherapy of our Polish colleagues is not known to us. Clinically: superficial skin lesions on the face. On the face are three ulcers of different sizes. Two ulcers on the cheeks and one on the nose. Palpation of the edges of the ulcers is very painful.
Diagnostic search for the etiology of this process. Consultation of a rheumatologist ̶ the goal of eliminating Wegener's disease, rheumatological diseases. Hematologist consultation ̶ exclude hematology. Infectionist consultation ̶ rule out parasitic diseases. Laboratory examination: biochemical blood test, immunogram, rheumatic tests. CT scan of the abdomen.
Consultation of a parasitologist. The diagnosis was not in doubt.The patient refused examination and treatment in the infectious diseases hospital. The further fate of this patient is not known to us. We want to draw the attention of doctors to the need for a thorough history taking. An epidemiological history is crucial in such cases.
Treatment of leishmaniasis is long and toxic. No method of treatment gives 100% of the result. The choice of treatment method will depend on the type of pathogen and the geographical location of the infection.This disease can be brought by tourists, students from relevant countries of the world to Ukraine.
30
Kravchenlko, V. A., A. V. Yurkevich, I. D. Ushnitski, A. V. Shcheglov, R. A. Saleev, and Yu L. Vasilyev. "Clinical and morphological studies of reactions of oral mucosa patients with digestive system disorders." Medical alphabet 1, no. 5 (February 15, 2019): 58–62. http://dx.doi.org/10.33667/2078-5631-2019-1-5(380)-58-62.
Full textAbstract:
Impaired functioning of various body systems have a significant effect on the morphofunctional state of the oral organs and, in particular, the periodontal complex. This effect is primarily due to significant metabolic disorders, systemic or local hemodynamic disorders, changes in the neurohumoral regulation of the immunological status. Among the diseases that have a direct impact on the state of periodontal disease, the leading position is occupied by lesions of the digestive system. In patients with gastric ulcer and duodenal ulcer, chronic gastritis and chronic cholecystitis, a high susceptibility of the teeth, periodontal and oral mucosa was detected. The dependence of the growth of pathological processes in the periodontium on the age of patients with various diseases of the gastrointestinal tract. According to a survey of patients with diseases of the gastrointestinal tract, 96 % needed treatment for dental and periodontal diseases, 51.1 % of removable and 62.8 % of bridges were considered unfit for use, 77.6-85.3 % of patients needed orthopedic dental care, of which 35.6 % had no dentures. In the study of proliferative processes of the oral mucosa of persons using removable prostheses in the pathology of the gastrointestinal tract, the prevalence of the average index of labeled nuclei, the label index, mitotic index and pathological mitoses in women was established, which indicates a more intensive regeneration process in them, in comparison with men, and is connected, apparently, with the sexual demorphism of the studied tissues.
31
Dong, L., S. LI, Z. Wu, F. Wang, S. Zhang, Q. LI, Y. Yu, et al. "SAT0250 CLINICAL CHARACTERISTICS AND THE DISEASE ACTIVITY OF BEHCET’S DISEASE IN CHINA: A STUDY BASED ON SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1068.1–1068. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1470.
Full textAbstract:
Background:Behcet´s disease (BD) is a systemic autoimmune disease that affects multiple organ systems with recurrent oral ulcers, genital ulcers and skin lesions. Behcet´s Disease Current Activity Form (BDCAF) and Electronic Medical Record-based Activity Index (EMRAI) are commonly used internationally to evaluate the disease activity of BD.Objectives:This study aimed to analyze the clinical characteristics, the level of disease activity, and the incidence of anxiety and depression for Chinese BD patients. Patients can perform self-management of disease with SSDM.Methods:SSDM is a series of doctor-patient interactive applications for self-management of patients with chronic diseases. Patients can perform self-assessment with SSDM and upload the data to their authorized doctors. The SSDM patients’ application system integrates the BDCAF and EMRAI into one scoring system. Patients could obtain scores of BDCAF and EMRAI by responding to one questionnaire through SSDM.Results:From Apr 2017 to Jan 2020, 719 BD patients from 166 hospitals used SSDM, with a mean age of 38.97±12.71 (14~81) years old, and median disease duration of 20.8 months. 719 patients performed BDCAF and EMRAI self-assessment 1321 times, 252 patients repeat assessments for 855 times. The mean score of BDCAF and EMRAI are 3.57±2.17 and 3.44±1.90, respectively. The matching degree of the two score was 0.8747.The most common clinical characteristics were oral ulcers (83.73%), ocular symptoms (62.03%), joint pain (50.07%). The comparative study between males and females revealed significant difference in the aspects of epididymitis (10.94% vs 0, p<0.001), genital ulcer (35.09% vs 44.93%, p=0.01), headache (24.15% vs 33.92%, p=0.01) and superficial thrombophlebitis (24.15% vs 33.92%, p=0.01). Table 1.Table 1.Clinical Characteristics of different systems in Chinese BD patients.Presence of clinical characteristicsTotalMalesFemalesP valueOral ulcer83.73% (602)86.42% (229)82.16% (373)0.14Genital ulcer41.31% (297)35.09% (93)44.93% (204)0.01*Epididymitis4.03% (29)10.94% (29)0 (0)<0.001**Erythema29.49% (212)29.43% (78)29.52% (134)0.98Skin lesions26.84% (193)28.68% (76)25.77% (117)0.4Superficial thrombophlebitis30.32% (218)24.15% (64)33.92% (154)0.01*Headache30.32% (218)24.15% (64)33.92% (154)0.01*Joint pain50.07% (360)51.32% (136)49.34% (224)0.61Arthritis14.60% (105)14.72% (39)14.54% (66)0.95Gastrointestinal involvement24.90% (179)27.92% (74)23.13% (105)0.15Ocular symptoms62.03% (446)62.64% (166)61.67% (180)0.79Nervous involvement23.78% (171)25.66% (68)22.69% (103)0.37Vascular involvement15.72% (113)18.11% (48)14.32% (65)0.18*P values are for the comparison between the males and females.Conclusion:Chinese BD patients can effectively perform BDCAF and EMRAI self-assessment with SSDM. The results of the assessment conducted by the two scoring systems are similar. The clinical characteristics of Chinese BD were different depending on gender.Acknowledgments: :Smart system of disease management (SSDM) was developed by Shanghai Gothic Internet Technology Co., Ltd.Disclosure of Interests:None declared
32
Goloeva, R. G., and Z. S. Alekberova. "Behсet's disease: intestinal damage." Rheumatology Science and Practice 56, no. 6 (January 22, 2019): 767–76. http://dx.doi.org/10.14412/1995-4484-2018-767-776.
Full textAbstract:
Behсet's disease (BD) is a systemic vasculitis of an unknown etiology characterized by repeated oral and genital ulcerations and involvement of the eyes, joints, blood vessels, and other organs. In BD, it is the organ pathology that determines the severity and prognosis of the disease. The most difficult and least studied version of such changes is intestinal damage. Its verification in BD is complicated by a variety of clinical manifestations, their similarity with inflammatory bowel diseases, the lack of sufficiently informative laboratory tests, and pathognomonic endoscopic and histological signs. Intestinal BD (IBD) can result in serious complications (severe bleeding, intestinal perforation, and fistula formation), which may not only considerably reduce the quality of life of the patient, but also cause his death. Treatment for IBD is not standardized; it is mainly empirical and is performed as cycles. The goal of its therapy is to achieve clinical remission, to heal intestinal ulcers, to reduce recurrence rates, and to prevent surgery. The cumulative frequency of surgical interventions is as follows: 20% of them are performed in the first year, 27–33% within 5 years, and 31–46% within 10 years after IBD diagnosis. One of the problems in the surgical treatment of patients with IBD is the risk of a recurrence that often requires repeat surgery. Thus, 2- and 5-year postoperative recurrence rates were 29.2 and 47.2%, respectively. The poor prognostic factors are young age (<40 years), high disease activity at the time of diagnosis, detection of crateriform or deep ulcers at colonoscopy, high C-reactive protein level, and history of laparotomy.
33
Gergianaki, I., A. Fanouriakis, C. Adamichou, G. Spyrou, N. Mihalopoulos, S. Kazadzis, L. Chatzi, P. Sidiropoulos, D. T. Boumpas, and G. Bertsias. "Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry." Lupus 28, no. 1 (December 6, 2018): 104–13. http://dx.doi.org/10.1177/0961203318816820.
Full textAbstract:
Background Examining urban–rural differences can provide insights into susceptibility or modifying factors of complex diseases, yet limited data exist on systemic lupus erythematosus (SLE). Objective To study SLE risk, manifestations and severity in relation to urban versus rural residence. Methodology Cross-sectional analysis of the Crete Lupus Registry. Demographics, residency history and clinical data were obtained from interviews and medical records ( N=399 patients). Patients with exclusively urban, rural or mixed urban/rural residence up to enrolment were compared. Results The risk of SLE in urban versus rural areas was 2.08 (95% confidence interval: 1.66–2.61). Compared with rural, urban residence was associated with earlier (by almost seven years) disease diagnosis – despite comparable diagnostic delay – and lower female predominance (6.8:1 versus 15:1). Rural patients had fewer years of education and lower employment rates. Smoking was more frequent among urban, whereas pesticide use was increased among rural patients. A pattern of malar rash, photosensitivity, oral ulcers and arthritis was more prevalent in rural patients. Residence was not associated with organ damage although moderate/severe disease occurred more frequently among rural-living patients (multivariable adjusted odds ratio: 2.17, p=0.011). Conclusion Our data suggest that the living environment may influence the risk, gender bias and phenotype of SLE, not fully accounted for by sociodemographic factors.
34
Goloeva, R. G., Z. S. Alekberova, T. A. Lisitsyna, E. A. Stepanova, and L. P. Orlova. "Intestinal manifestations of Behçet's disease." Terapevticheskii arkhiv 91, no. 5 (May 15, 2019): 111–19. http://dx.doi.org/10.26442/00403660.2019.05.000247.
Full textAbstract:
Behçet's disease (BD) is a systemic vasculitis of unknown origin, characterized by recurrences of the ulcerative process in the oral cavity and on the genitals, inflammatory damage of the eyes, joints, vessels and other organs. The severity and prognosis of BD determines organ pathology. Intestinal manifestations of BD (intestinal BD) are the least studied. Its verification in BD is complicated by the variety of clinical manifestations, their similarity with inflammatory bowel diseases, the lack of informative laboratory tests, pathognomonic endoscopic and histological signs. Intestinal BD can lead to serious complications (massive bleeding, intestinal perforation and fistula formation), which can not only significantly reduce the quality of the patient’s life, but also cause death. Treatment of intestinal BD is not standardized; it is mainly empirical and conducted courses. The purpose of therapy is to achieve clinical remission, healing of intestinal ulcers and prevention of surgery. The article presents a case of severe refractory intestinal BD, requiring twice emergency surgical care - removal of half and then the whole of the colon because of multiple perforations. A brief review of the literature is given and diagnostic difficulties of intestinal BD are discussed.
35
Coelho, Pedro, Carlos Menezes, Rita Gonçalves, Pedro Rodrigues, and Elena Seara. "Peripheral Ulcerative Keratitis Associated with HCV-Related Cryoglobulinemia." Case Reports in Ophthalmological Medicine 2017 (2017): 1–3. http://dx.doi.org/10.1155/2017/9461937.
Full textAbstract:
Purpose. To describe a case of peripheral ulcerative keratitis associated with type II cryoglobulinemia in the context of Hepatitis C infection. Methods. Case report and literature review. Results. A 36-year-old male patient presented to our emergency department with unilateral moderate pain in his right eye, associated with redness and photophobia. Medical background elicited a history of Hepatitis C and IV illicit drug abuse. Ocular examination revealed a BCVA of 20/30 of the affected eye and slight discomfort with eye movement. Biomicroscopy revealed a ring shaped peripheral corneal ulcer, with a dense white stromal infiltrate sparing the limbus, plus an adjacent area of mild anterior diffuse nonnecrotizing scleritis. No intraocular inflammation was present. Posterior segment was normal. The patient was placed under oral prednisolone (1 mg/Kg/day) with gradual tapering. A dramatic clinical response occurred, with complete resolution of the clinical condition. Systemic analytic workup aiming at autoimmune and infectious diseases was negative, except for high HCV-viral load and the presence of type 2 cryoglobulins. Conclusion. Albeit rare, cryoglobulinemia, even in the absence of systemic vasculitis, should be considered in the differential diagnosis of PUK, when systemic workout for autoimmune diseases is negative.
36
Keche, Prashant N., Nishikant P. Gadpayle, Surendra H. Gawarle, and Gaurav A. Chamania. "An observational study of benign oral lesions in central India." International Journal of Otorhinolaryngology and Head and Neck Surgery 3, no. 4 (September 22, 2017): 816. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20173201.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">The oral mucosa serves as a protective barrier against trauma, pathogens and carcinogenic agents. It can be affected by a wide variety of lesions and conditions, some of which are harmless while others may have serious complications. The appearance of benign oral soft tissue masses can occasionally resemble malignant tumors. </span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">Present study is an observational and cross sectional study under taken in the Department of ENT in Shri Vasant Rao Naik Government Medical College, Yavatmal. All cases of benign oral lesions were included in the study and following cases were excluded: malignant oral lesions, immunocompromised state and benign Oral lesions due to systemic diseases. </span></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Present study included 235 lesions of oral cavity which were clinically or histo-pathologically found to be benign in nature.<strong> </strong>Benign oral lesions were more commonly found in males with (70.2%) than females (29.8%), and M:F ratio was 2.3:1. most common benign oral lesions were found to be Oral Sub Mucus Fibrosis (26.8%) followed by Apthous ulcers (20.4%), Leukoplakia (18.3%) and Mucocele (17.1%). Least common benign oral lesions were found to be Minor Salivary Gland Tumor (MSGT) (1.7%) followed by Squamous Papilloma (2.1%), Ranula (2.1%) and Hemangioma (2.1). There was a male predominance in oral sub mucus fibrosis with M:F ratio of 9.5:1 followed by Leukoplakia with M:F ratio of 4.4:1. OSMF was found most commonly in 21-30 years age group with (57.1%). Followed by 11-20 years with (20.6%). No cases were found in ≤10 years, 51-60 and >60 years age group. </span></p><p class="abstract"><strong>Conclusions:</strong> <span lang="EN-IN">Most of the benign oral lesions have a predilection to transform into malignant lesions therefore imperative to diagnose the pre malignant lesions of oral cavity in an early stage where appropriate treatment can be given.</span></p>
37
Araruna, Maria Elaine, Pablo Silva, Maria Almeida, Renaly Rêgo, Raiff Dantas, Hilton Albuquerque, Ingrid Cabral, et al. "Tablet of Spondias mombin L. Developed from Nebulized Extract Prevents Gastric Ulcers in Mice via Cytoprotective and Antisecretory Effects." Molecules 26, no. 6 (March 12, 2021): 1581. http://dx.doi.org/10.3390/molecules26061581.
Full textAbstract:
Spondias mombin L. (Anacardiaceae) has a worldwide distribution and is present in all regions of Brazil. Its leaves, flowers and bark are used as teas in folk medicine to treat diseases of the digestive system. This study aimed to evaluate the acute non-clinical toxicity, gastroprotective activity, and the related mechanisms of action of nebulized extract and tablets based on dried Spondias mombin (SmNE). SmNE screening showed the presence of flavonoids (0.65%), polyphenols (25.50%), where the major compound is gallic acid. In the acute oral toxicity assay, a dose of 2000 mg/kg of SmNE administered orally in Swiss mice did not induce any behavioral changes. SmNE (250 or 500 mg/kg p.o) significantly reduced the ulcerative lesion area when compared to the control group in ethanol and non-steroidal anti-inflammatory drug (NSAIDs) models. Results showed that treatment with SmNE (250 mg/kg) reduced acid secretion and gastric content, accompanied with an increase in pH. Previous administration of indomethacin and glibenclamide reversed the protection provided by SmNE, confirming the participation of prostaglandins (PGs) and ATP-sensitive potassium channels (KATP) in its gastroprotective effect. The SmNE tablets met the pharmacopeial quality requirements with gastroprotective activity and similar protection in comparison to the isolated extract administrated. In conclusion, SmNe has a gastroprotective activity related to cytoprotective mechanisms, such as the participation of endogenous prostaglandins and KATP channels, having an anti-secretory effect with systemic action. The formulation obtained presented gastroprotective effects similar to the administration of the extract, the tablets showed favorable compression characteristics by the direct route and met the pharmacopeial quality requirements.
38
Hamasur, Kashan S. "Prevalence of Oral Manifestations of Inflammatory Bowel Disease in Patients Admitted to Sulaymaniyah teaching hospital – Iraq." AL-Kindy College Medical Journal 16, no. 1 (September 5, 2020): 47–53. http://dx.doi.org/10.47723/kcmj.v16i1.190.
Full textAbstract:
The aim of this study is to evaluate the association between IBD and oral symptom and mucosal lesions in patients with Crohn’s disease and ulcerative colitis
Methods: This is a cross-sectional study that has been done in (Kurdistan center for Gastroenterology and hepatology) of Teaching Hospital in Sulaymaniyah-Iraq, which included 101 patients previously diagnosed with Inflammatory Bowel Disease who were interviewed regarding manifestations of inflammatory bowel disease especially oral manifestations. Required data were collected through a specially designed questionnaire,
Results: The patients’ mean age was 45.74±12.58 years. Patients with ulcerative colitis and Crohn’s disease were not significantly different in terms of age, sex, smoking, and drinking alcohol (p>0.05), and it was seen that age groups 41-50 and 51-60, males, smokers, and drinkers were more affected by these two diseases. They were not significantly different in terms of chief complaint, drug history, oral hygiene, and disease duration (p>0.05). Most of the patients (78 out of 101) had fair or poor oral hygiene. The two groups of the patients were not significantly different in terms of oral manifestations and symptoms (p>0.05). The most common oral manifestations were found to be respectively angular cheilitis, aphthous ulcer, and diffuse lip swelling in both diseases. The most common symptoms were respectively dry mouth and halitosis.
Conclusion: This study revealed that dentists and oral and maxillofacial Medicine could involve in a diagnosis of IBD, by at least in the referral process, because patients in clinical setting may give a history of orofacial complaints giving a hint on possible systemic background of IBD
39
Chaudhary, A., NA Ingle, N. Kaur, and K. Dhankar. "Geriatric Dentistry: A Review." Journal of Oral Health and Community Dentistry 7, no. 3 (2013): 170–73. http://dx.doi.org/10.5005/johcd-7-3-170.
Full textAbstract:
ABSTRACT Education in geriatric medicine is in its infancy in India and geriatric dentistry is nonexistent. Poor oral health is linked to serious systemic diseases such as cardiovascular diseases and stroke. Edentulousness and paucity of prosthodontic rehabilitation prevent the elderly from choosing food that they like and deny them the pleasure of eating, which is essential for a feeling of wellbeing. Oral mucosal diseases and lesions are common in elderly people. Many older adults have pigmented and benign soft-tissue and hard-tissue conditions. Lichenoid mucosal lesions can also be caused by a variety of medications commonly prescribed in older patients. The prevalence of leukoplakia and lichen planus in older people ranges from 1.0 to 4.8% and 1.1 to 6.6%, respectively. Fifty percent of zoster patients over 60 years of age will develop postherpetic neuralgia that may persist for months or even years. Root surface caries result from an age-related condition that develops on cementum following gingival recession or as an extension of existing coronal caries onto the root surface coronal caries are also quite prevalent among older persons. A recent survey of 65-74-year-old in Madagascar observed that the mean number of DMFT was 20.2. In China, second national oral health survey revealed that the mean number of decayed and filled teeth was 2.5 at old age, and study in India confirmed this figure observed in China, the mean number of decayed teeth being 2.5. Denture stomatitis is a common oral mucosal lesion of clinical importance in old-age populations. The prevalence rate of stomatitis is reported within the range of 11-67% in complete denture wearers. Other major denture-related lesions include denture hyperplasia and traumatic ulcer; their prevalence rates in old-age denture wearers range from 4 to 26%.
40
Manandhar, A., A. Bhandari, and D. Kunwar. "Dental Awareness, Knowledge and Attitude among the Medical Practitioners in Pokhara, Nepal." Journal of Gandaki Medical College-Nepal 12, no. 2 (December 31, 2019): 23–27. http://dx.doi.org/10.3126/jgmcn.v12i2.27165.
Full textAbstract:
Introduction: Oral health is a window to our overall health. Negligence to oral health might have adverse effects on the general well being of a person. Hence, early detection and prompt treatment is of utmost importance. Lack of general medical practitioner’s knowledge of oral disease has been shown to contribute to delays in referral and treatment, thus significantly affecting the associated morbidity and mortality.
Methods: The present study was undertaken to assess knowledge, attitude and dental awareness among medical practitioners in Pokhara, Nepal. A list of medical practitioners was obtained from the NMA (Nepal Medical Association, Gandaki branch, Nepal) and sample size of 109 study subjects was calculated. A cross-sectional study was conducted among the medical practitioners. from March 2018 to April 2018. The data pertaining to their knowledge, attitude and awareness about oral health was gathered using a self-administered questionnaire. The data was analyzed using descriptive statistics.
Results: Results of the study showed that the medical practitioners had moderate to good knowledge about dentistry as 97.2% of the medical practitioners answered correctly saying that brushing tooth daily prevents tooth decay and periodontal disease Whereas, when asked about the changes in the oral cavity which most commonly is associated with progression towards oral cancer, only 46.8% answered correctly by responding to non-healing ulcer/ erosive lesions.
Conclusions: It is imperative that the dental/medical practitioners have good knowledge about the oral diseases and its systemic manifestations, so as to have timely referral and early treatment to prevent the associated morbidity and mortality.
41
Penev, B., G. Vasilev, D. Kyurkchiev, and S. Monov. "AB0815 FIRST DEGREE RELATIVES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - CLINICAL, SEROLOGICAL AND IMMUNOLOGICAL CORRELATIONS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1432.2–1432. http://dx.doi.org/10.1136/annrheumdis-2021-eular.511.
Full textAbstract:
Background:Antinuclear antibodies (ANA) have been unequivocally recognized as essential for diagnosis and play both pathogenic and diagnostic roles in systemic lupus erythematosus (SLE). SLE and ANA have also been found to be more often among relatives of SLE patients. ANA and other immunological changes are known to appear prior to the clinical onset of the disease and thus can be used as predictors. Studies have reported that relatives of SLE patients who later transitioned to SLE displayed more lupus-associated autoantibody specificities and had early clinical signs. They also displayed elevated baseline plasma levels of inflammatory mediators, including B-lymphocyte stimulator (BLyS) and interferon-associated chemokines, with concurrent decreases in levels of regulatory mediators, e.g. tumor growth factor (TGF)-β. Commonly recognized risk factors for SLE are signs of past Epstein-Barr (EBV) infection, use of estrogen drugs and current smoking. It seems that ANA, immunologic changes and risk factors have not been investigated together in relatives of SLE patients.Objectives:The aim of the study was to determine the relative prevalence of clinical signs of SLE or connective tissue disease (CTD), smoking, use of estrogen drugs and levels of circulating ANA, BLyS, IFN-α, TGF-β, anti-EBV viral capsid antigen (VCA) IgM and IgG antibodies among sera of FDR, non-FDR healthy individuals and SLE patients.Methods:Forty three FDRs of SLE patients were studied along with 15 SLE patients and 15 clinically healthy subjects as control groups. The FDRs and the healthy answered a questionnaire about early clinical signs of CTD, smoking and estrogen use history. The questionnaire was developed based on the existing Screening Questionnaire for Connective Tissue Diseases and current knowledge of most early signs of CTD. Blood samples were obtained and tested for ANA, both by indirect immunofluorescence and immunoblot, anti-dsDNA by ELISA. ELISA was also performed to measure levels of BLys, IFN-α, TGF-β, anti-EBV IgM and IgG.Results:More than half of the FDRs displayed ANA in titer 1:160 or more, with predominately AC-4 type of fluorescence according to International Classification on ANA Patterns (ICAP) compared to only AC-1 and AC-0 among patients and controls respectively. A correlation between the ANA titer and the number of complaints was found. This was particularly valid or reported skin complaints and oral ulcers which appeared more frequently when ANA was 1:320 or above (p=0,018 and 0,038 respectively). Furthermore, oral ulcerations showed positive correlation with the presence of anti-Ro60. No associations were found in the healthy group between reported complaints and ANA titers. Smoking and estrogen use did not differ across the three groups. Patients showed significant differences in levels of BLys (p=0,027), TGF-β (p=0,019) and anti-EBV IgG (p=0.041) compared to both FDRs and controls. Without reaching statistical significance, levels of TGF-β tend to split the FDR group into “healthy-like” and “SLE-like”.Conclusion:Our results show that FDR ANA levels are between those of SLE patients and healthy subject groups. This is consistent with previous studies. The data also suggest that ANA positivity correlates with reported complaints, some of which could be interpreted as very early clinical signs of SLE. Of note, anti-Ro60 is known to be among the earliest ANA that appear in “future” SLE patients and in this study they are related to oral complaints that could be caused by early sicca phenomena. Immunologically, our data support previous findings [1] that the FDRs are a heterogenic group with different “lupus-developing” potential.References:[1]Munroe МE. et al, Soluble Mediators and Clinical Features Discern Risk of Transitioning to Classified Disease in Relatives of Systemic Lupus Erythematosus Patients, Arthritis Rheumatol. 2017 March; 69(3): 630–642.Disclosure of Interests:Bogdan Penev: None declared, Georgi Vasilev: None declared, Dobroslav Kyurkchiev: None declared, Simeon Monov Speakers bureau: I have been paid for giving lectures on statistical data on efficacy of many pharmaceutical products on various companies
42
Kotloff, Karen L., Marcelo B. Sztein, Steven S. Wasserman, Genevieve A. Losonsky, Susan C. DiLorenzo, and Richard I. Walker. "Safety and Immunogenicity of Oral Inactivated Whole-CellHelicobacter pylori Vaccine with Adjuvant among Volunteers with or without Subclinical Infection." Infection and Immunity 69, no. 6 (June 1, 2001): 3581–90. http://dx.doi.org/10.1128/iai.69.6.3581-3590.2001.
Full textAbstract:
ABSTRACT Helicobacter pylori infection of the gastric mucosa can be found in approximately 50% of the world's population and is associated with a range of pathology, including peptic ulcer, atrophic gastritis, and gastric cancer. To explore immunization as a strategy for preventing and treating H. pylori-associated disease, we assessed the safety and immunogenicity in healthy adults of a formalin-inactivated, oral H. pylori whole-cell (HWC) vaccine, administered with or without mutant Escherichia coli heat-labile toxin (LTR192G) as a mucosal adjuvant. In a dose-response study, 23 subjects with or withoutH. pylori infection were vaccinated with either 2.5 × 106 HWC, 2.5 × 108 HWC, or 2.5 × 1010 HWC, plus 25 μg of LTR192G. Thereafter, a randomized study was conducted in which 18 H. pylori-infected subjects were assigned, in a double-blind fashion, to receive either 2.5 × 1010 HWC plus placebo-adjuvant, placebo-vaccine plus 25 μg of LTR192G, placebo-vaccine plus placebo-adjuvant, or 2.5 × 1010 HWC plus 25 μg of LTR192G. Diarrhea (six subjects), low-grade fever (five subjects), and vomiting (two subjects) were observed, usually after the first dose. Significant rises in geometric mean mucosal (fecal and salivary) anti-HWC immunoglobulin A antibodies occurred amongH. pylori-infected and uninfected subjects following inoculation with 2.5 × 1010 HWC plus 25 μg of LTR192G. Moreover, among H. pylori-negative volunteers, this regimen induced significant lymphoproliferative responses in 5 of 10 subjects and gamma interferon production responses to H. pylori sonicate in 7 of 10 subjects. There was no evidence that vaccination eradicatedH. pylori in infected volunteers. These results suggest that it is possible to stimulate mucosal and systemic immune responses in humans to H. pylori antigens by using an HWC vaccine.
43
Thomas, Kim S., Jonathan M. Batchelor, Fiona Bath-Hextall, Joanne R. Chalmers, Tessa Clarke, Sally Crowe, Finola M. Delamere, et al. "A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease." Programme Grants for Applied Research 4, no. 18 (December 2016): 1–488. http://dx.doi.org/10.3310/pgfar04180.
Full textAbstract:
BackgroundSkin diseases are very common and can have a large impact on the quality of life of patients and caregivers. This programme addressed four diseases: (1) eczema, (2) vitiligo, (3) squamous cell skin cancer (SCC) and (4) pyoderma gangrenosum (PG).ObjectiveTo set priorities and reduce uncertainties for the treatment and prevention of skin disease in our four chosen diseases.DesignMixed methods including eight systematic reviews, three prioritisation exercises, two pilot randomised controlled trials (RCTs), three feasibility studies, two core outcome initiatives, four funding proposals for national RCTs and one completed national RCT.SettingSecondary care, primary care and the general population.ParticipantsPatients (and their caregivers) with eczema, vitiligo, SCC and PG, plus health-care professionals with an interest in skin disease.InterventionsOur three intervention studies included (1) barrier enhancement using emollients from birth to prevent eczema (pilot RCT); (2) handheld narrowband ultraviolet light B therapy for treating vitiligo (pilot RCT); and (3) oral ciclosporin (Neoral®, Novartis Pharmaceuticals) compared with oral prednisolone for managing PG (pragmatic national RCT).ResultsSystematic reviews included two overarching systematic reviews of RCTs of treatments for eczema and vitiligo, an umbrella review of systematic reviews of interventions for the prevention of eczema, two reviews of treatments for SCC (one included RCTs and the second included observational studies), and three reviews of outcome measures and outcome reporting. Three prioritisation partnership exercises identified 26 priority areas for future research in eczema, vitiligo and SCC. Two international consensus initiatives identified four core domains for future eczema trials and seven core domains for vitiligo trials. Two pilot RCTs and three feasibility studies critically informed development of four trial proposals for external funding, three of which are now funded and one is pending consideration by funders. Our pragmatic RCT tested the two commonly used systemic treatments for PG (prednisolone vs. ciclosporin) and found no difference in their clinical effectiveness or cost-effectiveness. Both drugs showed limited benefit. Only half of the participants’ ulcers had healed by 6 months. For those with healed ulcers, recurrence was common (30%). Different side effect profiles were noted for each drug, which can inform clinical decisions on an individual patient basis. Three researchers were trained to PhD level and a dermatology patient panel was established to ensure patient involvement in all aspects of the programme.ConclusionsFindings from this programme of work have already informed clinical guidelines and patient information resources. Feasibility studies have ensured that large national pragmatic trials will now be conducted on important areas of treatment uncertainty that address the needs of patients and the NHS. There is scope for considerable improvement in terms of trial design, conduct and reporting for RCTs of skin disease, which can be improved through wider collaboration, registration of trial protocols and complete reporting and international consensus over core outcome sets. Three national trials have now been funded as a result of this work. Two international initiatives to establish how best to measure the core outcome domains for eczema and vitiligo are ongoing.Trial registrationCurrent Controlled Trials Barrier Enhancement for Eczema Prevention (BEEP) (ISRCTN84854178 and NCT01142999), Study of Treatments fOr Pyoderma GAngrenosum Patients (STOP GAP) (ISRCTN35898459) and Hand Held NB-UVB for Early or Focal Vitiligo at Home (HI-Light Pilot Trial) (NCT01478945).FundingThis project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full inProgramme Grants for Applied Research; Vol. 4, No. 18. See the NIHR Journals Library website for further project information.
44
Lyons, Roger M., Sharon T. Wilks, David J. Friedman, Shelby A. Young, and Gail Brown. "Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)." Blood 120, no. 21 (November 16, 2012): 4394. http://dx.doi.org/10.1182/blood.v120.21.4394.4394.
Full textAbstract:
Abstract Abstract 4394 Introduction: Idiopathic chronic neutropenia (ICN) is a group of diseases characterized by low circulating neutrophils, recurrent fevers, mucosal inflammation, and systemic infections. The risk of complications is inversely proportional to the absolute neutrophil count (ANC), with the most severe occurring with ANC of < 0.5 × 109/L. Most patients respond to daily s.c. administration of granulocyte colony stimulating factors (G-CSF); however, some patients do not respond. Patients undergoing G-CSF therapy also often have bone and muscle pain, thrombocytopenia and splenomegaly, complicating therapy. Ezatiostat, a glutathione S-transferase (GST) inhibitor that activates Jun kinase, promoting growth and maturation of hematopoietic progenitors, is an investigational agent in development for treatment of ICN. This report describes 4 patients with longstanding ICN who responded to ezatiostat, all of whom prior to treatment had frequent hospitalizations for sepsis, prolonged courses of antibiotics and poor response to myeloid growth factors. Methods: Patients (pts) with severe ICN and inadequate ANC response to G-CSF were enrolled in this phase 2 trial. After initial starting dose of 2000 mg in divided doses twice daily (b.i.d.) dose-equilibration over 4 weeks, pts were treated with ezatiostat daily for 3 weeks followed by 1 week off. Treatment was given until lack of ANC response or unacceptable toxicity. Clinical benefit was determined by ANC response, infection-free periods, antibiotic use and hospitalizations for infections. Results: Four female pts, age range 23–63, with median ANC of 200 (50–400) were enrolled. Patient 1 is 62 y.o. with longstanding history of infections and treatment with G-CSF. Before entering study, she had recurrent ear, labial, left thigh, pulmonary and sinus infections despite growth factor treatment, to which she had severe reactions. Baseline white blood cell (WBC)/ANC ratio was 2.2/0.7. WBC/ANC improved with ezatiostat for 4 mo to 3.62/1.71 and infections resolved. Patient 2, a 63 y.o. with ICN for 26 years, had a median baseline WBC/ANC on G-CSF treatment of 3.1/.180 and a history of multiple hospital admissions for sepsis, non-healing perineal and decubitus ulcers, and recurrent high fevers within 4 days of cessation of parenteral antibiotics, necessitating resumption. Post-ezatiostat treatment median ANC was 3.1 (range 1.6–3.75) with a persistent infection-free period of over 22 mo with no hospitalizations or antibiotic therapy required. Patient 3, a 23 y.o. with ICN since age 10, initially responded to G-CSF but stopped responding despite injections b.i.d., and ANC never rose above 1000. Her last hospitalization was for methicillin-resistant staphylococcus aureus skin infection, upper respiratory infection with cervical adenopathy, and oral ulcers. She had infections every 3 months and baseline WBC/ANC of 1.4/0.13. She had minimal response over 4 mo of observation, with highest values 2.65/0.92 and median ANC of 0.40, but had no further bacterial infection or use of G-CSF. Patient 4, a 39 y.o. with ICN of 10 years' duration, had severe bone pain with G-CSF and responses were brief (1–2days). Previously, she had hospital admissions and emergency room visits 4–5 times a year and was ill 2–3 times a week with recurrent urinary tract infections, pneumonias (4–5 times per year), oral ulcers, sinus and gastrointestinal infections, furuncles, and infection after dental work. Baseline WBC/ANC was 1.23/0.20. Currently, her WBC/ANC is 1.50/0.26. While ANC did not increase, infection rate decreased and she had no ER visits or admissions for over 5 mo. She responded to a single 300 mcg dose of of G-CSF with an ANC of 1.0 for a week, suggesting re-sensitization to G-CSF. Most common ezatiostat-related adverse events were grade 1 nausea, abnormal urine/stool odor, and dysgeusia. Conclusions: Ezatiostat, a novel GSTP1-1 inhibitor and jun kinase modulator as treatment of patients with ICN and grade 4 neutropenia not responsive to myeloid growth factors, results in a durable ANC response and clinically significant reductions in serious infections. Results suggest a potential role for ezatiostat as an oral therapy alternative or adjunct to G-CSF in the treatment of ICN in patients who are not responsive to G-CSF. Response to this targeted therapy may also give insight into the pathophysiology of ICN and further study is warranted. Disclosures: Lyons: Telik, Inc.: Research Funding. Wilks:Telik, Inc.: Research Funding. Friedman:Telik, Inc.: Research Funding. Young:Telik, Inc.: Employment, Equity Ownership. Brown:Telik, Inc.: Employment, Equity Ownership.
45
Kibar Ozturk, Melike. "Suspected cutaneous anthrax in rural areas." Journal of Infection in Developing Countries 13, no. 02 (February 28, 2019): 118–22. http://dx.doi.org/10.3855/jidc.10318.
Full textAbstract:
Introduction: Cutaneous anthrax (CA), a zoonotic infectious disease is an important endemic public health disease in rural areas around the world, accounting for 95% of anthrax cases.
Methodology: Fifty patients with CA were diagnosed by the presence of characteristic skin lesions and positive response to treatment. Twenty-nine patients had been treated with oral ciprofloxacin or doxycyclin for 14 days and 21 patients had been treated with intramuscular procaine penicillin for 7 days. The demographic risk factors, characteristics and treatment of CA in rural areas were evaluated. The responses to two different systemic medications were compared using χ2 test.
Results: Twenty-two males and 28 females were included in this study. The predominant skin lesions were black eschar, ulcer and swelling of the skin. The predilection sites were the hand and fingers. The most common route of contamination for both male and female patients was handling raw meat. The most common occupation was housewife for female patients and animal industry for male patients. The patients under ciprofloxacin or doxycyclin administration responded better to treatment; pain at lesion site and new lesions at the time of treatment were significantly lower. Secondary infection appeared to be higher in patients under procaine penicillin administration, although this difference was not statistically significant.
Conclusions: In rural areas that lack medical facilities with diagnostic tools, in the presence of black eschar, rapid diagnosis and treatment of CA is essential. The administration of a broad-spectrum antibiotic is recommended as the first line treatment of suspected CA.
46
Edenius, C., G. Ekström, J. Kolmert, R. Morgenstern, P. Stenberg, P. J. Jakobsson, and G. Tornling. "SAT0315 INHIBITION OF MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES-1) BY GS-248 REDUCES PROSTAGLANDIN E2 BIOSYNTHESIS WHILE INCREASING PROSTACYCLIN IN HUMAN SUBJECTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1103.2–1103. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5503.
Full textAbstract:
Background:Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the formation prostaglandin (PG) E2from cyclooxygenase derived PGH2(1, 2). Inhibition of mPGES-1 leads to reduction of pro-inflammatory PGE2, while in vessels there is a concomitant increase of vasoprotective prostacyclin (PGI2) via shunting of PGH2(3,4). Apart from relieving symptoms in experimental animal models of inflammation, inhibitors of mPGES-1 cause relaxation of human medium sized arteries(4)and resistance arteries(5). The prostaglandin profile following mPGES-1 inhibition, explains the anti-inflammatory effects and also opens for the possibility of treating inflammatory diseases with concomitant vasculopathies. GS-248 is a potent and selective inhibitor of mPGES-1 exhibiting sub-nanomolar IC50in human whole bloodex vivo.Objectives:To evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of GS-248.Methods:Healthy males and females (age 18–73 years) were included in the study. Six cohorts were administrated single oral doses of 1-300mg GS-248 (n=36) or placebo (n=12), three cohorts were administered once daily doses of 20-180mg GS-248 (n=18) or placebo (n=12) over ten days. In addition, 8 subjects were treated in a separate cohort with 200mg celecoxib bid for ten days. Blood samples were drawn for measurement of GS-248 exposure and production of PGE2after LPS incubationex vivo. The content of PGE2and PGI2metabolites was measured in urine. All analyses were performed by LC-MS/MS.Results:GS-248 was safe and well tolerated at all tested dose levels. Maximum plasma concentration was achieved 1 - 2.5 hours after dosing, and half-life was about 10 hours. Induced PGE2formationex vivo,catalyzed by mPGES-1, was completely inhibited for 24 hours after a single low dose (40mg) of GS-248. In urine, GS-248 dose-dependently reduced the excretion of PGE2metabolite by more than 50% whereas the excretion of PGI2metabolite increased more than twice the baseline levels. In the celecoxib cohort urinary metabolites of both PGE2and PGI2were reduced with approx 50%.Conclusion:GS-248 at investigated oral doses was safe and well tolerated. There was a sustained inhibition of LPS induced PGE2formation in whole blood. In urine, there was a metabolite shift showing reduced PGE2and increased PGI2, while celecoxib reduced both PGE2and PGI2metabolites. This suggests that selective inhibition of mPGES-1 results in systemic shunting of PGH2to PGI2formation, leading to anti-inflammatory and vasodilatory effects, while preventing platelet activation. The results warrant further evaluation of GS-248 in inflammatory conditions with vasculopathies such as Digital Ulcers and Raynaud’s Phenomenon in Systemic Sclerosis.References:[1]Korotkova M, Jakobsson PJ. Persisting eicosanoid pathways in rheumatic diseases. Nat Rev Rheumatol. 2014;10:229-41[2]Bergqvist F, Morgenstern R, Jakobsson PJ. A review on mPGES-1 inhibitors: From preclinical studies to clinical applications. Prostaglandins Other Lipid Mediat. 2019;147:106383[3]Kirkby NS, et al. Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis. Cardiovasc Res. 2020[4]Ozen G, et al. Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI2: a safer alternative to COX-2 inhibition. Br J Pharmacol. 2017;174:4087-98[5]Larsson K, et al. Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone. Br J Pharmacol. 2019;176:4625-38Disclosure of Interests:Charlotte Edenius Shareholder of: Gesynta Pharma, Consultant of: Gesynta Pharma,, Gunilla Ekström Shareholder of: Gesynta Pharma, Consultant of: Gesynta Pharma,, Johan Kolmert Consultant of: Gesynta Pharma,, Ralf Morgenstern Shareholder of: Gesynta Pharma, Employee of: Gesynta Pharma, Patric Stenberg Shareholder of: Gesynta Pharma, Employee of: Gesynta Pharma, Per-Johan Jakobsson Shareholder of: Gesynta Pharma, Grant/research support from: Gesynta Pharma, AstraZeneca,, Göran Tornling Shareholder of: Gesynta Pharma, Vicore Pharma,, Consultant of: Gesynta Pharma, Vicore Pharma, AnaMar
47
Ueda, T., Hideyuki Ogata, Yusuke Kojima, and Eri Ishida. "Cytomegalovirus oral ulcers." Infection 42, no. 1 (October 29, 2013): 235. http://dx.doi.org/10.1007/s15010-013-0540-x.
Full text
48
Della Rossa, A., M. Doveri, A. D'Ascanio, A. Tavoni, A. Consensi, R. Neri, L. Bazzichi, and S. Bombardieri. "Oral sildenafil in skin ulcers secondary to systemic sclerosis." Scandinavian Journal of Rheumatology 40, no. 4 (June 6, 2011): 323–25. http://dx.doi.org/10.3109/03009742.2011.569755.
Full text
49
Babu, NChaitanya, and AndreaJoan Gomes. "Systemic manifestations of oral diseases." Journal of Oral and Maxillofacial Pathology 15, no. 2 (2011): 144. http://dx.doi.org/10.4103/0973-029x.84477.
Full text
50
Napeñas, Joel J. "Oral Manifestations of Systemic Diseases." Atlas of the Oral and Maxillofacial Surgery Clinics 25, no. 2 (September 2017): i. http://dx.doi.org/10.1016/s1061-3315(17)30028-8.
Full text